Table 1.
Patient Characteristics
| Age (median) | 64 | |
|---|---|---|
| Gender |
Female: Male: |
17 (41%) 24 (59%) |
| Lymphoma entity |
LBCL: MCL: tFL: |
35 (85%) 5 (12%) 1 (2%) |
| Ann Arbor Stage |
I: II: III: IV: |
6 (15%) 6 (15%) 7 (17%) 22 (54%) |
| IPI |
1: 2: 3: 4: 5: |
7 (17%) 13 (32%) 13 (32%) 4 (10%) 4 (10%) |
| CAR T Product |
Tisagenlecleucel: Axicabtagene ciloleucel: Brexucabtagene autoleucel: Lisocabtagene maraleucel: |
20 (58,8%) 13 (14,7%) 5 (23,5%) 3 (2,9%) |
| Bridging |
Chemotherapy: Radiation: Immunotherapy: Combined therapy: No bridging: |
21 (51%) 5 (12%) 2 (5%) 3 (7%) 10 (24%) |
| LDH (median) |
Apheresis: Prior Lymphodepletion: |
343 U/L 277 U/L |
CAR, chimeric antigen receptor; LBCL, large B cell lymphoma; IPI, International Prognostic Index; LDH, lactate dehydrogenase; MCL, mantle cell lymphoma; tFL, transformed follicular lymphoma